Biotech Decliners: Peregrine Pharmaceuticals (NASDAQ:PPHM), CytRx Corporation (NASDAQ:CYTR), PTC Therapeutics (NASDAQ:PTCT), Amicus Therapeutics (NASDAQ:FOLD)

Technology Stocks News 3

Peregrine Pharmaceuticals (NASDAQ:PPHM) announced its earnings results on Friday. The company reported ($0.06) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.06). Peregrine Pharmaceuticals (NASDAQ:PPHM) stock performance was -8.05% in last session and finished the day at $2.40. Traded volume was 14.14million shares in the last session and the average volume of the stock remained 4.31million shares. The beta of the stock remained 1.40. Peregrine Pharmaceuticals (NASDAQ:PPHM) insider ownership is 0.20%.

CytRx Corporation (NASDAQ:CYTR), a biopharmaceutical research and development firm specializing in oncology, on Wednesday declared financial results for the 12 months concluded on December 31, 2013, and also gave an overview of latest accomplishments and upcoming milestones for its clinical development programs. CytRx Corporation (NASDAQ:CYTR) dropped -6.17 percent to $5.32 Friday on volume of 3.19million shares. The intra-day range of the stock was $5.25 to $5.67. CytRx Corporation (NASDAQ:CYTR) has a market capitalization of $224.02million.

PTC Therapeutics Inc. (NASDAQ:PTCT) posted fourth-quarter net loss attributable to common stockholders of $17.9 million, or $0.75 per share, compared to a net loss of $6.3 million, or $1,380.13 per share in the year-ago period. PTC Therapeutics, Inc. (NASDAQ:PTCT)’s stock on Mar 7, 2014 reported a decrease of -7.13% to the closing price of $31.00. Its fifty two weeks range is $13.03-$34.65. The total market capitalization recorded $911.50million. The overall volume in the last trading session was 615,975.00million shares. In its share capital, PTCT has 23.80million outstanding shares.

Amicus Therapeutics Inc (NASDAQ:FOLD) was downgraded by Zacks from a “neutral” rating to an “underperform” rating in a research note issued to investors on Tuesday. On Friday, shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) dropped -5.37% to close the day at $2.29. Company return on investment (ROI) is -71.10% and its monthly performance is recorded as
-11.92%. Amicus Therapeutics, Inc. (NASDAQ:FOLD) quarterly revenue growth is -0.43%.

Signup for free to be the first to receive exclusive free links. Now in your mailbox!
Join over 15,000 subscribers
Send me links

Your information will not be shared to anyone